Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer

Journal of Surgical Oncology

Volumn 97, Issue 5, 2008, Pages 433-438

  Sasaki, Ken ^a   Natsugoe, Shoji ^a   Ishigami, Sumiya ^a   Matsumoto, Masataka ^a   Okumura, Hiroshi ^a   Setoyama, Tetsuro ^a   Uchikado, Yasuto ^a   Kita, Yoshiaki ^a   Tamotsu, Kiyokazu ^a   Sakurai, Toshihide ^a   Owaki, Tetsuhiro ^a   Aikou, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

CXCL12; CXCR4; Lymph node metastasis; Microvessel density; Submucosal esophageal squamous cell carcinoma

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; CARCINOMA, SQUAMOUS CELL; CHEMOKINE CXCL12; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES;

EID: 41549113859     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20976     Document Type: Article

References (34)

1. Maehara Y, Oshiro T, Endo K, et al.: Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 1996;119:397-402.
2. Greenson JK, Isenhart CE, Rice R, et al.: Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994;73:563-569.
3. Cutait R, Alves VA, Lopes LC, et al.: Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991;34:917-920.
4. Clare SE, Sener SF, Wilkens W, et al.: Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997;4:447-451.
5. Matsumoto M, Natsugoe S, Okumura H, et al.: Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer. J Gastrointest Surg 2006;10:1016-1022.
6. Matsumoto M, Natsugoe S, Ishigami S, et al.: Rapid immunohistochemical detection of lymph node micrometastasis during operation for upper gastrointestinal carcinoma. Br J Surg 2003;90:563-566.
7. Matsumoto M, Natsugoe S, Nakashima S, et al.: Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. Cancer Lett 2000;153:189-197.
8. Natsugoe S, Mueller J, Stein HJ, et al.: Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: Frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998;83:858-866.
9. Scotton CJ, Wilson JL, Milliken D, et al.: Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res 2001;61:4961-4965.
10. Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
11. Kijima T, Maulik G, Ma PC, et al.: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-6311.
12. Zhou Y, Larsen PH, Hao C, et al.: CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002;277:49481-49487.
13. Schrader AJ, Lechner O, Templin M, et al.: CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002;86:1250-1256.
14. Taichman RS, Cooper C, Keller ET, et al.: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
15. Uchida D, Begum NM, Almofti A, et al.: Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 2003;290:289-302.
16. Hwang JH, Hwang JH, Chung HK, et al.: CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88:408-416.
17. Phillips RJ, Burdick MD, Lutz M, et al.: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676-1686.
18. Mori T, Doi R, Koizumi M, et al.: CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004;3:29-37.
19. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997) Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.
20. Listrom MB, Dalton LW: Comparison of keratin monoclonal antibodies MAK-6, A E1:AE3, and CAM-5.2. Am J Clin Pathol 1987;88:297-301.
21. Woodcock-Mitchell J, Eichner R, Nelson WG, et al.: Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol 1982;95:580-588.
22. Weidner N, Semple JP, Welch WR, et al.: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
23. Choi JY, Jang KT, Shim YM, et al.: Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: Comparison with positron emission tomography. Ann Surg Oncol 2006;13:1054-1062.
24. Kaifi JT, Yekebas EF, Schurr P, et al.: Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005;97:1840-1847.
25. Salmaggi A, Gelati M, Pollo B, et al.: CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: A single-institution study in 50 patients. J Neurooncol 2005;74:287-293.
26. Ishigami S, Natsugoe S, Okumura H, et al.: Clinical implication of CXCL12 expression in gastric cancer. Ann Surg Oncol 2007;14:3154-3158.
27. Jiang YP, Wu XH, Shi B, et al.: Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol 2006;103:226-233.
28. Almofti A, Uchida D, Begum NM, et al.: The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int J Oncol 2004;25:65-71.
29. Laverdiere C, Hoang BH, Yang R, et al.: Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-2567.
30. Schimanski CC, Schwald S, Simiantonaki N, et al.: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005;11:1743-1750.
31. Tachibana K, Hirota S, Iizasa H, et al.: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;393:591-594.
32. Wang J, Wang J, Dai J, et al.: A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res 2007;67:149-159.
33. Liang Z, Wu T, Lou H, et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CX CR4. Cancer Res 2004;64:4302-4308.
34. Tamamura H, Hori A, Kanzaki N, et al.: T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003;550:79-83.